Atlas FDA

Alinity m HBV

FDA premarket approval P200013/S008 · decided 2022-06-08

Approval details

PMA number
P200013
Supplement
S008
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
Alinity m HBV
Generic name
Hepatitis Viral B DNA Detection
Applicant
Abbott Molecular, Inc.
Date received
2022-05-10
Decision date
2022-06-08
Days to decision
29 days
Decision code
OK30
Product code
MKT
Advisory committee
Microbiology
Expedited review
No
Location
Des Plaines, IL
Statement
Use of an alternate component in a septum cap assembly since the current material is no longer available.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Alinity m HCV (K252102)Abbott Molecular, Inc.2025-09-25
Alinity m EBV (09N43-095) (K243489)Abbott Molecular, Inc.2025-07-28
Alinity m CMV (K243485)Abbott Molecular, Inc.2025-07-01
Alinity m BKV (K241921)Abbott Molecular, Inc.2025-03-24
Alinity m Resp-4-Plex (K241573)Abbott Molecular, Inc.2025-02-14
Alinity m HSV 1 & 2 / VZV (K233349)Abbott Molecular, Inc.2024-05-03
Alinity m STI Assay (K222379)Abbott Molecular, Inc.2023-03-03
Alinity m EBV AMP Kit (List No. 09N43-095), Alinity m EBV CTRL Kit (List No. 09N43-085), Alinity m EBV CAL Kit (List No. 09N43-075) (K212778)Abbott Molecular, Inc.2022-07-15